Biotechnology companies Valinor Discovery and Renew Biotechnologies have announced a strategic collaboration to generate what they say will be the largest clinical multi-omics dataset for neurological disorders. Designed to improve the prediction of disease onset and therapeutic responses, the initiative aims to provide Valinor access to multimodal datasets derived from thousands of patients spanning Alzheimer’s […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!